secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indivior Pharmaceuticals, Inc. (INDV)
CIK:        0001625297
Form:       8-K
Filed at:   2026-09-15T20:28:36+00:00
Accession:  0001625297-26-000028
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indivior accelerates RB copacker supply deal termination to Jan 15, 2027
------------------------------------------------------------------------

- Indivior UK and Reckitt Benckiser Healthcare UK terminated Copacker Supply Agreement effective Jan 15, 2027, vs original Dec 31, 2027.
- RB to manufacture additional volumes of SUBOXONE/SUBUTEX tablets before termination; Indivior identified a new supplier.
- Indivior to pay RB costs (under absorption, asset disposal, redundancy, incentive) that are fixed/capped and stated as not material.
- New supplier agreement not expected to be material and enforceable only after validation of manufacturing process.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625297/000162529726000028/0001625297-26-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625297/000162529726000028/indv-20260909.htm
  HTML page:      https://secwatch.observer/filing/0001625297-26-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer